Browse the evidence

Weight loss is associated with improvement in cardiovascular risk, menstrual cycles, ovulation, and pregnancy rate in women with obesity and PCOS.

Weight loss should be prioritized in treatment plans for women with obesity and PCOS to improve health outcomes.

Lifestyle modifications are often the first-line intervention for improving hormonal imbalances and menstrual cycles in women with PCOS.

Clinicians should consider lifestyle modifications as a primary strategy in managing PCOS.

Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Two-thirds of respondents reported reduced appetite, food cravings, or body weight.

Practitioners can expect that a significant portion of patients may experience appetite reduction and weight loss with Ozempic.

Tirzepatide yields greater weight loss and broad metabolic benefits.

Clinicians may prefer tirzepatide for patients focused on weight loss and metabolic improvements.

Exogenous β-hydroxybutyrate (BHB) supplementation significantly reduced fat mass by 2 kg and improved body fat percentage in overweight and obese adults.

Practitioners may consider BHB supplementation as a strategy to enhance fat loss in overweight and obese clients.

Lean mass was largely preserved with no declines in resting metabolic rate (RMR) in the BHB group.

BHB supplementation may help maintain lean mass during caloric restriction.

Patients treated with GLP-1RAs achieved a mean absolute weight loss of 7.33 kg compared to baseline.

GLP-1RAs can be effective for weight loss in IBD patients.

GLP-1 receptor agonist type drugs can help patients achieve considerable weight loss.

Practitioners can consider GLP-1 RAs as a treatment option for weight loss in obese patients.

Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.

Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.

Achieving ≥ 5% total weight loss (TWL) is associated with a higher risk ratio (RR) of type 2 diabetes remission (RR = 7.88).

Practitioners should encourage patients to aim for at least 5% weight loss to improve diabetes remission rates.

Achieving ≥ 5% TWL is associated with a higher RR of hypertension remission (RR = 2.23).

Encouraging weight loss of at least 5% may help patients achieve better blood pressure control.

Achieving ≥ 5% TWL leads to significant mean differences in metabolic risk factors including HbA1c, fasting plasma glucose, and blood pressure.

Weight loss of at least 5% can lead to significant improvements in key metabolic health indicators.

Semaglutide is endorsed as a secondary treatment for improving glycemic control in type 2 diabetes mellitus (T2DM).

Practitioners can consider semaglutide as a secondary option for patients with T2DM to improve blood sugar control.

Semaglutide is being investigated for its potential in combating obesity.

Practitioners should stay informed about the potential use of semaglutide for obesity management.

Semaglutide can help regulate blood sugar levels and decrease long-term health complications related to diabetes.

Practitioners can use semaglutide to manage blood sugar levels and reduce diabetes-related complications.

Intermittent fasting has cardiometabolic effects in persons with prediabetes and type 2 diabetes.

Healthcare providers may consider intermittent fasting as a potential dietary intervention for patients with prediabetes and type 2 diabetes.

Nutritional deficiencies, particularly in vitamins and minerals, necessitate dietary counseling and supplementation for post-weight-loss patients.

Dietary counseling should be integrated into post-weight-loss care.

Semaglutide consistently produces substantial reductions in body weight and visceral fat, accompanied by improvements in blood pressure, glycemic control, inflammatory markers, and hepatic steatosis.

Practitioners can expect significant improvements in metabolic health markers with semaglutide use.

SELECT demonstrated a significant reduction in major adverse cardiovascular events in adults with overweight or obesity and established atherosclerotic cardiovascular disease, independent of diabetes status.

Semaglutide may significantly lower the risk of cardiovascular events in at-risk populations.

Liraglutide reduced total body mass and lowered absolute and percent android fat over 18 days.

Liraglutide may be effective for weight loss in individuals with type 2 diabetes.

FDA-approved medications such as orlistat, phentermine/topiramate, bupropion/naltrexone, and liraglutide have significantly improved weight-loss outcomes.

Practitioners can consider these medications as effective options for weight management.

Semaglutide and tirzepatide achieve weight-loss outcomes comparable to bariatric surgery.

These medications may be considered as alternatives to surgical weight loss options.